COVID-19 treatments | A glance at the most recent reported drugs, which may close to the operational phase.

COVID-19 treatments | A glance at the most recent reported drugs, which may close to the operational phase.
Sirvan Abbasbeigi,^1,*
1. Master of cellular and molecular science / biochemistry field of study, Islamic Azad University (IAU), Science and Research branch, Sanandaj, Iran
Introduction: Due to the increasing spread of the Coronavirus, 2019 (COVID-19), the competition for the most successful possible solution has become very popular among different countries. Therefore, addressing the issue of which is the next most likely candidate to enter the global market; It is a question that sooner or later every country must answer.
Methods: This study planned based on the latest published information on drugs that are currently undergoing the fourth clinical phase of the estuary, has tried to cover the common concern, which means that recent reports indicate the importance of which of the existing or newly synthesized drugs in the control of this disease? In this review, extensive investigations in PubMed, Scopus, and Google Scholar have been performed using keywords including Budesonide, Lenalidomide, Linagliptin, Acetylcysteine, and Gamolenic acid Accordingly, the most important research papers about this subject based on the quality and level of pieces of evidence have been collected, categorized, and discussed.
Results: The findings suggest that the introduced chemical structures are evidence of measurable success on a laboratory scale, but there are no reliable reports of the high potency of these drugs to control or treat COVID-19 in the long term. It is clear that much of the existing treatment methods have resulted out from an understanding of the previous 2 outbreaks, particularly the SARS-CoV outbreak which shares similarities with the novel strain of the Coronavirus. However, to generate treatments with high efficacy, the unique features of SARS-CoV-2 must be understood to a greater extent, especially its spike protein. Besides these, different serotypes are being identified in different countries with a slight variation which may respond to a different host response, pathogenesis, and symptoms in different regions.
Conclusion: In conclusion, FDA approved most of these drugs permanently or under a specific condition, it is obvious that scientists had to get along with trial and error these days to overcome the probable upcoming catastrophe.
Keywords: Coronavirus, COVID-19, Treatments, Laboratory experiments, Trial and error, FDA.